Supplementary Table 1. Baseline characteristics and treatment response after 6 monthly administrations of anti-CGRP MAbs in patients with and without medication overuse

	Without MO (n=40)	With MO (n=99)	P value
Demographics			
Age, mean (SD) years	45.2 (10.4)	47.7 (9.09)	0.158[§]
Gender (female), n (%)	32 (80.0)	81 (81.8)	0.803[†]
Disease characteristics			
Duration of migraine disease, mean (SD) y	24.3 (11.9)	26.4 (13.2)	0.373[§]
Chronification time, mean (SD) y	12.0 (6.4)	12.3 (7.6)	0.793[§]
Aura, n (%)	18 (45.0)	23 (23.2)	**0.011[†]**
Allodynia, n (%)	22 (55.0)	49 (49.5)	0.557[†]
Unilateral pain side, n (%)	33 (82.5)	75 (75.8)	0.387[†]
Pain quality, n (%)			
Oppressive	14 (35.0)	48 (48.5)	0.148[†]
Throbbing	23 (57.5)	67 (67.6)	0.256[†]
HDM, mean (SD), d/mo	23.2 (5.6)	23.3 (5.8)	0.894[§]
MDM, mean (SD), d/mo	16.7 (6.4)	17.8 (6.6)	0.396[§]
Headache pain intensity, mean (SD), 0-3 score	1.58 (0.50)	1.70 (0.47)	0.168[§]
Preventive treatment			
Anti-CGRP Treatment, n (%)			
Erenumab 140mg	27 (67.5)	69 (69.7)	0.800[†]
Galcanezumab 120mg (240mg initial dose)	13 (32.5)	30 (30.3)	
Prior preventive classes failures, n (%)			
3 Classes	9 (22.5)	8 (8.1)	
4 Classes	10 (25.0)	39 (39.4)	0.284[†]
≥5 Classes	21 (52.5)	52 (52.5)	
Prior BTX-A efficacy[*], n (%)			
Partial	17/33 (51.5)	54/93 (58.1)	0.515[†]
Failure	16/33 (48.5)	39/93 (41.9)	
Concomitant preventive treatment, n (%)	31 (77.5)	65 (65.7)	0.171[†]
Oral concomitant medication, n (%)	31 (77.5)	57 (57.6)	**0.027[†]**
BTX-A concomitant medication, n (%)	13 (32.5)	38 (38.4)	0.515[†]
Acute medication			
Acute medication frequency, mean (SD), d/mo	6.8 (4.4)	19.2 (7.0)	**<0.0001[§]**
NSAIDs frequency, mean (SD), d/mo	3.3 (2.9)	9.1 (8.5)	**<0.0001[§]**
Triptans frequency, mean (SD), d/mo	3.5 (3.2)	12.9 (7.7)	**<0.0001[§]**
BZD frequency, mean (SD), d/mo	1.3 (0.3)	3.5 (0.9)	0.108
Acute medication burden, mean (SD), p/mo	8.3 (5.4)	26.9 (11.7)	**<0.0001[§]**

Disease impact, disability and burden			
Disability (MIDAS), median [IQR]	54.5 [66.3]	85.0 [67.0]	**$0.005^{‡}$**
Headache-related impact (HIT-6), mean (SD)	72.1 (30.1)	68.4 (15.1)	$0.473^{§}$
Anxiety (BAI), median [IQR]	20.0 [25.3]	19.0 [20.0]	$0.717^{‡}$
Depression (BDI-II), median [IQR]	14.5 [17.8]	11.0 [17.0]	$0.589^{‡}$
Treatment response rate at 6 months			
HDM 50% RR, n (%)	17 (42.5)	53 (53.5)	$0.239^{‡}$
MDM 50% RR, n (%)	23 (57.5)	63 (63.6)	$0.500^{‡}$

Bold font indicates statistically significant variables.
[*]126/139 patients were previously treated with BTX-A
[§]Significance assessed with independent *t*-test
[†]Significance assessed with Fisher's exact test or linear trend chi-square test (preventive classes failures)
[‡]Significance assessed with Mann-Whitney U test
MO: medication overuse; SD: standard deviation; IQR: interquartile range; y: years; d/mo: days per month; p/mo: pills per month; HDM: headache days/month; MDM: migraine days/month; BTX-A: OnabotulinumtoxinA; NSAIDs: non-steroidal anti-inflammatory drugs; MIDAS: migraine disability assessment; HIT-6: headache impact test; BAI: Beck anxiety inventory; BDI-II: Beck depression inventory-second edition. MAbs: monoclonal antibodies